Exelixis Corp - Wutah bathi EPS kuartalan EXEL

Ownership of patents for targeted oncology therapy allows Exelixis, Inc. (EXEL) to command premium pricing due to low demand elasticity. The growth rate of quarterly earnings per share reflects current dynamics, where the actual level is 22.80. Stability is driven by Cabometyx sales, while market positions are strengthened by a narrow specialization in treating complex solid tumors of the kidneys and liver.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan exelixis.com (EXEL): kanggo periode 04.07.2022 - 14.11.2026

Rincian analitis perusahaan Exelixis, Inc.

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham Exelixis|EXEL - Rega prakiraan analis

- rincian nilai pasar emiten:

Kapitalisasi pasar Exelixis Corp|EXEL - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Exelixis|EXEL - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku exelixis.com|EXEL - Aset Neraca Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Exelixis, Inc.|EXEL - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Exelixis, Inc.|EXEL - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Exelixis Corp|EXEL - Utang jangka dawa|Utang jangka cendhak perusahaan Exelixis|Indikator likuiditas cepet exelixis.com

- rincian bathi lan kelipatan pasar:

EXEL - Bathi pungkasan|Bathi mangsa ngarep Exelixis, Inc.|EXEL - Rasio rega pasar marang bathi resik|Pangali Forward P/E Exelixis Corp|EXEL - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Exelixis Corp|EXEL - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Exelixis|EXEL - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan exelixis.com|EXEL - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Exelixis, Inc.

- indikator pendapatan dodolan lan penghasilan bisnis:

EXEL - Pendapatan tahunan perusahaan|Volume dodolan mangsa ngarep perusahaan Exelixis|EXEL - Rega marang dodolan|Multiplikator Forward P/S Exelixis Corp

Pambiji fundamental perusahaan:Exelixis - EXEL

This indicator measures the dynamics of net earnings per share by linking quarterly changes to daily market value. For Exelixis, Inc. (EXEL), the recorded quarterly EPS growth confirms the monetization of Cabozantinib patents within the targeted therapy segment. The narrowing volatility on this chart signals stabilizing revenues. However, excessive stagnation may mask an emerging negative trend. The indicator's steady trajectory verifies the fundamental strength of the business.

Analisis perusahaan pesaing